What's Happening?
Researchers at Stony Brook Medicine have confirmed the first human case of Bourbon virus in New York, a potentially fatal tick-borne infection with no available vaccine or treatment. Michael Larkin, a resident of Brookhaven, was diagnosed retrospectively
after suffering from severe symptoms in 2021. The virus, carried by the lone star tick, has been expanding its range due to warmer winters and increased deer populations. Despite the virus's presence, no standard clinical laboratory in the U.S. can test for it, leading to underdiagnosis and untreated cases. The virus was first identified in Kansas in 2014, and only a handful of cases have been confirmed in the U.S. since then.
Why It's Important?
The confirmation of Bourbon virus in New York highlights the growing public health challenge posed by tick-borne diseases. The lack of a standard diagnostic test means many cases go unconfirmed, hindering effective treatment and public health responses. This situation underscores the need for expanded viral surveillance and the development of clinical testing and assays. The spread of the lone star tick, the virus's vector, into new regions raises concerns about increased human exposure and potential outbreaks. The situation calls for increased funding and research to develop diagnostic tools and potential treatments.
What's Next?
Efforts to address the Bourbon virus challenge include securing increased funding for Lyme and tick-borne disease programs, as advocated by Congressman Nick LaLota. Researchers are calling for expanded viral surveillance and the development of diagnostic tests. The lack of confirmed cases impedes treatment research, but studies on antiviral candidates like favipiravir and molnupiravir show promise in animal models. Public health officials may need to enhance awareness and education about tick-borne diseases and preventive measures to mitigate the risk of infection.
